An observational study in Sarcopenia, sponsored by The Cleveland Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by The Cleveland Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Sarcopenia with a site in United States — 37 open to participants now, 47 under way, 1 of them phase 3. Sarcopenia · United States.
Among the 187 studies in Sarcopenia with a site in United States, this one is the 20th largest by planned enrollment of the 40 observational ones that give a count, is one of 10 that started in 2021, is one of 40 observational ones, reaches primary completion later than 23 of the 46 other live ones, and was the 132nd registered.
1,330 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.
Browse Sarcopenia studies →37 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
Kennesaw State University · Sites in United States
Ages 65–85 · Healthy volunteers
Health Discovery Labs · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 3 · Phase 4 5
First in 1995; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 40 across the 146 interventional studies, 70 across the 40 observational. Of the 126 that completed or were terminated, 43 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 187 have an industry lead sponsor. The 10 most frequent:
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 120 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
The Cleveland Clinic has 5 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
16 of the studies in Sarcopenia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT06722508University of California, DavisExercise and Nutritional Prehabilitation for Head and Neck Cancer Patients | 2026-12 |
| NCT07029243University of California, San FranciscoPrehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis | 2026-12 |
| NCT06628349Texas A&M UniversityPrandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein | 2026-12 |
| NCT03998202Wake Forest University Health SciencesMyopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 187 studies in Sarcopenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the proposed research is to investigate Magnetic Resonance (MR) Fingerprinting and P-MRS (Phosphorus-31 MR Spectroscopy) imaging for characterization of skeletal muscle in heart failure patients with sarcopenia. Heart failure patients with and without sarcopenia will be scanned using MR Fingerprinting and an existing Post-exercise phosphocreatine (PCr) recovery MR imaging protocol to obtain characteristic profiles of quantitative T1, T2, and PCr recovery rate.
Sarcopenia is a common comorbidity and predictor of mortality in heart failure that is characterized by a loss of muscle mass and functional strength. Sarcopenia, in heart failure and other chronic diseases, has been consistently predictive of poor outcomes. However, current tools to identify the presence of sarcopenia, such as functional tests and questionnaires are indirect, non-specific, and not effective until patients have reached an overtly cachectic state and significant muscle deterioration has already occurred. MRI can serve an important, noninvasive role in the assessment and management of sarcopenia by providing insight as to tissue microstructure and mitochondrial function. For example, MRI has shown significant changes in T2 relaxation time, diffusion fractional anisotropy, and lipid content in skeletal muscle of pre-frail/frail patients as compared to healthy volunteers. Post-exercise phosphocreatine (PCr) recovery, evaluated using phosphorus-31 (P) MR spectroscopy Imaging(P-MRSI), has shown impairment of mitochondrial function in pre-frail elderly as compared to active elderly. MR fingerprinting (MRF) is a promising tool for tissue characterization via rapid, robust quantification of T1 and T2 relaxation and has been shown to be accurate and reproducible across sites. Despite applications in neuroimaging and cardiac imaging, MRF has had limited use in musculoskeletal imaging and has not been investigated for use in characterizing sarcopenia. Similarly, P-MRS imaging has not been employed for evaluation of sarcopenia in heart failure patients, a population which may have a unique etiology from other sarcopenia phenotypes. Characterization of sarcopenia may support a range of rapidly developing treatment options in this population. While evidence suggests exercise therapy can improve frailty status, for instance in 39% of patients at 12 month follow-up, it is not yet well-understood which patients will respond to treatment. With a range of treatment options such as nutritional supplementation, hormone therapy, and cardiovascular drugs, MRF and P-MRSI could serve as powerful noninvasive tools to provide a personalized approach for sarcopenic phenotypes, match them to appropriate therapy, and monitor therapeutic response.
Heart Failure and Healthy volunteers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Heart failure patients
Healthy Volunteers
Exclusion Criteria:
Heart failure patients
Healthy volunteers (controls)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclusion criteria: * Age \> or = 40 yrs * Stable chronic heart failure * Systolic dysfunction determined by cardiac MRI with left ventricle ejection fraction 40% or less Exclusion criteria: • Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease Contraindications to MRI such as: * Heart pacemaker/defibrillator * Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires * Cochlear implant or other ear implants * Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity) * Programmable shunt * Aneurysm clips and coils * Stents • Filters (for example, blood clot filters) * Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)
Inclusion criteria: * Age \> or = 40 yrs * No diagnosed heart failure or sarcopenia Exclusion criteria • Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease Contraindications to MRI such as: * Heart pacemaker/defibrillator * Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires * Cochlear implant or other ear implants * Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity) * Programmable shunt * Aneurysm clips and coils * Stents * Filters (for example, blood clot filters) * Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)
Anticipated Results
This proposal is expected to produce information as to the change in T1, T2, muscle area, fat fraction, and PCr recovery rate values for heart failure patients with sarcopenia as compared to non-sarcopenic volunteers. Future work will expand upon this study to evaluate to progression of sarcopenia, and evaluate the prognostic value of imaging biomarkers (T1, T2, muscle area, fat fraction, PCr recovery) in predicting heart failure and sarcopenic related outcomes.
Time frame: 3 years
Started Apr 2021 (actual). Primary completion is estimated for Jan 2027, 69 months after the start.
Of 191 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 69 months is above that.
Counting every sponsor, half of 193 studies reached it within 26 months; a quarter within 12 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jul 2026 → Jan 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.